Search the Newsreel

Outlook Therapeutics CEO Robert Jahr acquires shares and warrants for $0

Outlook Therapeutics CEO Robert Jahr recently acquired 151,515 shares of common stock and an equal number of warrants. This transaction occurred at a combined public offering price of $0.99 per unit, amounting to $0, with each warrant allowing the purchase of one share at …

Outlook Therapeutics (OTLK) CEO purchases 151,515 shares and matching warrants

Outlook Therapeutics (OTLK) CEO Robert Charles Jahr purchased 151,515 shares of common stock and 151,515 accompanying warrants on August 14, 2026. The transaction occurred in an underwritten public offering at a combined price of $0.99 per share and warrant. The warrants are exercisable immediately …

Outlook Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:OTLK) 2026-08-14

Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call

Outlook Therapeutics (OTLK) Q3 Earnings Miss Highlight Valuation Challenges

Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Outlook Therapeutics, Inc. (OTLK) reported a Q3 loss of $0.09 per share, aligning with analyst expectations, but missed revenue estimates significantly with $0.01 million compared to an expected $1.5 million. The company's stock has underperformed the S&P 500 this year, and while the current …

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

Outlook Therapeutics reported its third-quarter fiscal year 2026 financial results, highlighting the FDA approval of LYTENAVA™ for wet age-related macular degeneration (wet AMD). The company is preparing for a U.S. commercial launch by the end of 2026, with an estimated potential to exceed $500 …

FDA-approved LYTENAVA targets wet AMD; U.S. launch planned by year-end 2026

Outlook Therapeutics (OTLK) reported a Q3 fiscal 2026 net loss of $20.3 million but highlighted the FDA approval of LYTENAVA™ (bevacizumab-vikg) for wet age-related macular degeneration, the only FDA-approved ophthalmic bevacizumab for this condition. The company is preparing for a U.S. launch by year-end …

Outlook Therapeutics Q3 Results: Loss narrows to 8 cents per share

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most

Outlook Therapeutics (OTLK) Q3 Earnings Preview: Valuation Chall

Why is Outlook Therapeutics stock plunging today?

Outlook Therapeutics Inc. (OTLK) stock is plummeting due to its announcement of a public offering of 55.6 million shares and accompanying warrants at a significant discount, causing substantial dilution for existing shareholders. The capital raise aims to fund the commercial launch of LYTENAVA, its …

Outlook Therapeutics slides after pricing $55M securities offering

Outlook Therapeutics (OTLK [https://seekingalpha.com/symbol/OTLK]) shares fell nearly 15% in premarket trading Thursday after the company priced a public offering of 55.6M shares and warrants for gross proceeds of about $55M. The combined offering price is $0.99 per share and accompanying warrant, with the warrants …

Outlook Therapeutics Prices $55 Mln Offering To Support LYTENAVA Launch; Stock Down

(RTTNews) - Outlook Therapeutics, Inc. (OTLK), a biopharmaceutical company, priced a public offering of 55.56 million shares and accompanying warrants to purchase up to 55.56 million shares at a combined public offering price of $0.99 for each share of common stock and accompanying warrant. …

Outlook Therapeutics Starts Public Offering of Stock, Warrants

Outlook Therapeutics has initiated a public offering of its stock and warrants. This development follows recent positive news for the biopharmaceutical company, including FDA acceptance of a resubmitted Biologics License Application for its lead product candidate, ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab for treating …

Outlook Therapeutics reports $1.4 million fiscal 2025 LYTENAVA revenue

OTLK Up More Than 300% in 3 Months: Here's What You Should Know

Outlook Therapeutics (OTLK) shares have surged over 300% in three months, driven by the FDA approval of its drug Lytenava for wet age-related macular degeneration (wet AMD). The company anticipates launching Lytenava in the U.S. by the end of 2026, which is expected to …

OTLK Stock Rocket Nearly 140%: FDA's Lytenava FDR Approval Pushes Stock On Track For Best Week On Record

Outlook Therapeutics (OTLK) stock surged nearly 140% after the FDA granted its appeal following a Formal Dispute Resolution (FDR) process for its eye disease drug, Lytenava. The FDA's decision indicates sufficient evidence for the drug's effectiveness against wet AMD, leading Outlook Therapeutics to plan …

Outlook Therapeutics to Report Third Quarter Fiscal 2026 Financial Results and Host Corporate Update Call on August 14, 2026

Outlook Therapeutics, Inc. will report its financial results for the third quarter of fiscal year 2026 and host a corporate update call on August 14, 2026, at 8:30 AM ET. The call will be led by CEO Bob Jahr and CFO Lawrence A. Kenyon. …

Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Outlook Therapeutics, Inc. (OTLK) is projected to exceed earnings estimates for the quarter ended June 2026, with an expected year-over-year increase in earnings despite lower revenues. The company's Zacks Earnings ESP of +42.31% combined with a Zacks Rank #3 suggests a high probability of …

Outlook Therapeutics CEO and CFO to Host Aug. 14 Update

Outlook Therapeutics Inc (OTLK) News, Articles, Events & Latest Updates

This page compiles recent news and updates for Outlook Therapeutics Inc (OTLK), focusing on developments related to its wet AMD drug, Lytenava. Key events include the FDA approval of Lytenava, discussions around its potential market impact, and upcoming Q3 earnings reports. The articles highlight …

Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?

We expect Outlook Therapeutics OTLK to beat expectations when it reports third-quarter fiscal 2026 results later this month. In the last reported quarter, the company delivered a negative earnings surprise of 33.33%. The Zacks Consensus Estimate for revenues is pegged at $1.20 million, while …

Outlook Therapeutics, Inc. Revenue Breakdown – NASDAQ:OTLK

Outlook Therapeutics, Inc. (NASDAQ: OTLK) reported a revenue of $1.41 million USD last year, primarily from its Ophthalmic Formulation segment, a decrease from $8.15 million USD the previous year. The United States was the largest contributor to this revenue. The company's financial overview highlights …

Is Outlook Therapeutics (OTLK) Fully Valued As FDA Approval Reshapes Its Prospects?

Outlook Therapeutics (OTLK) recently received FDA approval for LYTENAVA, its ophthalmic bevacizumab, for neovascular age-related macular degeneration, significantly impacting its investment outlook. Despite a near 3x share price increase in 90 days, followed by a 34.59% drop in 30 days, the company's valuation is …

Wet AMD Drug Secures First FDA-Approved Bevacizumab Status

Outlook Therapeutics Inc. (OTLK:NASDAQ) has received FDA approval for LYTENAVA, making it the first FDA-approved ophthalmic bevacizumab for wet age-related macular degeneration (wet AMD). This approval opens up access to an estimated US$8.5 billion U.S. market and is expected to provide 12 years of …

Outlook Therapeutics (OTLK) Stock Looks Cheap On Hope But Pricey On Book Value

Outlook Therapeutics (OTLK) has seen a significant stock decline over five years, but recent FDA approval for its lead drug, LYTENAVA, has brought renewed attention. While the approval provides hope for improved revenues, the stock's valuation picture remains inconclusive due to a negative shareholder …

Outlook Therapeutics (OTLK) Is Down 24.3% After Landmark FDA Wet AMD Drug Approval - Has The Bull Case Changed?

Outlook Therapeutics (OTLK) shares dropped 24.3% following FDA approval for LYTENAVA, a drug for wet age-related macular degeneration, despite securing 12 years of exclusivity in an $8.5 billion market. The investment focus has shifted from approval to successful U.S. launch and reimbursement, but financing …

Outlook Therapeutics (OTLK) director purchases 95,398 common shares

Outlook Therapeutics director Faisal Ghiath Sukhtian purchased 95,398 shares of common stock at $1.0482 per share on July 29, 2026. This transaction increased his direct holdings to 220,972 common shares. The purchase was an open-market or private transaction and was not made under a …

Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On Friday, the U.S. Food and Drug Administration (FDA) approved Outlook Therapeutics Inc.'s ONS-5010/LYTENAVA (bevacizumab-vikg, bevacizumab gamma) for neovascular age-related macular degeneration (nAMD), commonly known as wet …

Outlook Therapeutics, Inc. (NASDAQ:OTLK): When Will It Breakeven?

This article examines when Outlook Therapeutics, Inc. (NASDAQ:OTLK) is expected to achieve breakeven profitability. It analyzes the company's financial performance and projections to forecast its path to profitability. The analysis helps investors understand the timeline for OTLK to become financially self-sufficient.

Outlook Therapeutics’ Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIG

BTIG upgraded Outlook Therapeutics to 'Buy' with a $4 price target after the FDA approved its wet AMD therapy, Lytenava, positioning it as a potential preferred anti-VEGF treatment in the $8.5 billion U.S. retina market. Despite previous regulatory setbacks and competition from lower-cost alternatives, …

Outlook Therapeutics shares climb after FDA clears LYTENAVA for wet AMD

Outlook Therapeutics (NASDAQ:OTLK) shares surged after the FDA approved LYTENAVA for wet AMD, making it the first and only FDA-approved ophthalmic formulation of bevacizumab for this condition. The positive momentum was further bolstered by a BTIG analyst upgrade from Neutral to Buy with a …